Related Experiment Video
Updated: Feb 15, 2026

Microfluidic Device for the Separation of Non-Metastatic MCF-7 and Non-Tumor MCF-10A Breast Cancer Cells Using AC Dielectrophoresis
Published on: August 11, 2022
Barbigerone reverses multidrug resistance in breast MCF-7/ADR cells
Xiuxia Li1, Li Wan2, Fang Wang1
1Department of pharmacy, East Branch of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
Abstract:
Development of agents to overcome multidrug resistance (MDR) is one of the important strategies in cancer chemotherapy, and P-glycoprotein (P-gp) correlates with the degree of resistance. As a naturally occurring isoflavone, whether barbigerone (BA) could reverse MDR, is unknown. In this paper, we evaluated effects of BA on reversing P-gp mediated MDR of adriamycin (ADR)-resistant human breast carcinoma (MCF-7/ADR) cells. BA (0.5 μM) treatment showed strong potency to increase ADR cytotoxicity toward MCF-7/ADR cells. It was also demonstrated that BA time- and dose-dependently increased accumulations of ADR and reduced the efflux in MCF-7/ADR cells, pretreatment of these cells with BA might relocalized ADR to the nuclei. Furthermore, the results also revealed that BA did not affect P-gp, but alter P-gp ATPase activity. Intravenous administration of BA significantly increased anticancer efficacy of ADR to MCF-7/ADR xenograft model in nude mice. These results revealed that BA might reverse P-gp mediated MDR through inhibition of ATPase activity, which indicated a novel use of BA as a potent candidate for cancer chemotherapy.
Insights
Barbigerone (BA) effectively reverses multidrug resistance (MDR) in cancer by inhibiting P-glycoprotein (P-gp) ATPase activity, enhancing adriamycin
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
- P-glycoprotein (P-gp) is a key factor contributing to MDR.
- Barbigerone (BA), a natural isoflavone, has potential anticancer properties.
Purpose of the Study:
- To investigate the potential of barbigerone (BA) to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR).
- To evaluate the effects of BA on adriamycin (ADR) resistant breast cancer cells (MCF-7/ADR).
Main Methods:
- Cell-based assays using MCF-7/ADR cells to assess cytotoxicity and drug accumulation.
- In vivo studies using a xenograft mouse model.
- Analysis of P-gp ATPase activity.
Main Results:
- BA (0.5 μM) significantly enhanced adriamycin (ADR) cytotoxicity in MCF-7/ADR cells.
- BA increased intracellular ADR accumulation and reduced its efflux in a time- and dose-dependent manner.
- BA inhibited P-gp ATPase activity, not P-gp expression, and improved ADR efficacy in vivo.
Conclusions:
- Barbigerone (BA) effectively reverses P-gp mediated multidrug resistance (MDR).
- BA's mechanism involves the inhibition of P-gp ATPase activity.
- BA shows promise as a novel therapeutic agent to enhance cancer chemotherapy.
Related Concept Videos
Resistivity
Resistance
Reversible and Irreversible Processes
Diode: Reverse bias
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...

